Tag: Cancer Drugs

Many patients who are diagnosed with cancer will require treatment with cancer drugs. Treatment with cancer drugs is usually led by a doctor known as a medical oncologist.

Japan’s MHLW Approved Foundation Medicine CDx for Roche’s Rozlytrek in Lung Cancer

japan
Chugai Pharmaceutical, a subsidiary of Roche, announced that Japan's Ministry of Health, Labor, and Welfare has granted additional approval of Foundation Medicine's FoundationOne CDx Cancer Genomic Pr...

NICE Rejected Roche’s Tecentriq for Untreated SCLC in Adults

roche
The UK National Institute for Health and Care Excellence (NICE) has issued draft guidance against routine NHS coverage for Roche's Tecentriq (atezolizumab) in combination with carboplatin and etoposid...

Lynparza Approved for gBRCAm Metastatic Pancreatic Adenocarcinoma Treatment

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that Lynparza (olaparib) has been approved in the US for the maintenance treatme...

FDA Recommended KEYTRUDA for Treatment of Certain Patients with NMIBC

fda
Merck, known as MSD outside the United States and Canada, announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) voted 9-4 in favor of recommending...

GSK Announced Full Results from Belantamab Mafodotin DREAMM-2 Study

gsk
GlaxoSmithKline announced full results from the DREAMM-2 study, with data showing that belantamab mafodotin was associated with an overall response rate (ORR) of 31% in patients with relapsed/refracto...

Bristol-Myers Squibb Presented Positive Clinical Results from CC-486 Study

blood
Bristol-Myers Squibb Company announced clinical results from the QUAZAR AML-001 study, evaluating investigational agent CC-486 as maintenance therapy in a broad population of patients with front-line,...

Ardelyx Announced Positive Results from Tenapanor Study

clinical-trials
Ardelyx, Inc., a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, reported positive topline results from ...

Lenvima Accepted by NMPA for Additional Indication of Differentiated Thyroid Cancer

Eisai Co., Ltd. has announced that LENVIMA (generic name: lenvatinib), the orally available kinase inhibitor discovered by Eisai, has been accepted by the National Medical Products Administration of C...

NICE Approved Pfizer’s Ibrance for Treatment of Metastatic Breast Cancer

pfizer
The UK National Institute for Health and Care Excellence (NICE) has approved Pfizer’s Ibrance (palbociclib) for use in combination with fulvestrant for the treatment of women with hormone receptor pos...

Heraeus Expanded HPAPI Production

Company's multimillion euro investment will enable it to meet growing market demands from clients providing cancer treatments. Heraeus Pharmaceutical Ingredients, a business line of Heraeus Precious ...

3P Biopharmaceuticals, In3Bio to Collaborate in Novel Anti-Tumor Treatment Development

3P Biopharmaceuticals, a contract development and manufacturing organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has been chosen by In3Bio, a UK based bi...

Chugai Anticancer Agent/Anti-PD-L1 Launched in UK

Chugai Pharmaceutical Co., Ltd. announced that an anticancer agent/anti-PD-L1 (Programmed Death-Ligand 1) monoclonal antibody Tecentriq Intravenous Infusion 840 mg has been listed on the National Hea...

Blackstone Group Ready to Invest $400m in JV with Ferring

Blackstone Group Inc said it will invest $400 million in a joint venture with Swiss drug company Ferring that is working on an experimental gene therapy for bladder cancer, the private equity giant’s ...

Takeda Announced Updated Data from Phase 3 Trial of Alunbrig versus Crizotinib

clinical-trial
Takeda Pharmaceutical Company Limited announced updated data from the Phase 3 ALTA-1L trial, which evaluated ALUNBRIG versus crizotinib in adults with advanced anaplastic lymphoma kinase-positive (ALK...

FDA Approved New Treatment Option for Patients with Chronic Lymphocytic Leukemia

As part of Project Orbis, a collaboration with the Australian Therapeutic Goods Administration (TGA) and Health Canada, the U.S. Food and Drug Administration granted supplemental approval to Calquence...

BAVENCIO® Approved in Russia for Metastatic Merkel Carcinoma Treatment

merck kgaa
The Merck and Pfizer Alliance announced that the Ministry of Health of the Russian Federation has approved BAVENCIO® (avelumab, avelumab), as monotherapy in previously treated patients with metastatic...